Lila Sciences

Lila Sciences is an American autonomous AI-for-science company headquartered in Cambridge, Massachusetts, founded in 2023 by Geoffrey von Maltzahn (Flagship Pioneering general partner and serial biotech entrepreneur) and other founding-team members from Flagship Pioneering, the Cambridge-based biotech venture-creation firm. Lila Sciences explicitly positions itself as building autonomous AI scientists with end-to-end laboratory-experiment-execution capability, distinguishing itself from peer biology-AI labs through autonomous physical-laboratory infrastructure. As of April 2026, Lila Sciences is one of the principal commercial autonomous-AI-for-science startups, with a $200 million Series A in March 2025 led by ARCH Venture Partners and other investors at approximately $1.3 billion valuation.

At a glance

• Founded: 2023 in Cambridge, Massachusetts, by Geoffrey von Maltzahn and other Flagship Pioneering team members.
• Status: Private. Series A in March 2025 at approximately $1.3 billion valuation.
• Funding: Approximately $300 million-plus cumulative private capital. Series A of $200 million in March 2025 led by ARCH Venture Partners with Flagship Pioneering, General Catalyst, and other participants.
• CEO: Geoffrey von Maltzahn, Co-Founder and Chief Executive Officer. Flagship Pioneering general partner and serial biotech entrepreneur.
• Other notable leadership: Senior research and engineering leadership across the autonomous-laboratory program.
• Open weights: Limited. Lila Sciences develops commercial autonomous AI-for-science technology rather than open-research output.
• Flagship outputs: Autonomous AI scientists with end-to-end laboratory-experiment-execution capability; autonomous-laboratory infrastructure; continued commercial-development through 2024 to 2026.

Origins

Lila Sciences was founded in 2023 by Geoffrey von Maltzahn and other founding-team members from Flagship Pioneering, the Cambridge-based biotech venture-creation firm with history founding Moderna, Foghorn Therapeutics, and other biotech ventures. The founding thesis was explicitly oriented around autonomous AI scientists with end-to-end laboratory-experiment-execution capability, distinguishing the company from peer biology-AI labs through autonomous physical-laboratory infrastructure.

The 2023 to 2024 stealth period built autonomous-laboratory infrastructure and AI-system research. The March 2025 Series A of $200 million at approximately $1.3 billion valuation, led by ARCH Venture Partners with Flagship Pioneering, General Catalyst, and other participants, was the company's most consequential public-facing transition.

The 2025 to 2026 period has continued autonomous-laboratory research and commercial-product development.

Mission and strategy

Lila Sciences's mission is to build autonomous AI scientists with end-to-end laboratory-experiment-execution capability for biology research applications. The strategy combines three threads. First, the AI-system research for autonomous experimental design and analysis. Second, the autonomous-laboratory infrastructure with end-to-end experimental-execution capability. Third, commercial-development relationships with Flagship Pioneering portfolio companies and other biotech partners.

The competitive premise reflects Lila Sciences's distinct positioning combining autonomous-AI research with autonomous-laboratory infrastructure, distinguishing the company from peer biology-AI software-only startups.

Distribution channels include direct commercial-development relationships with Flagship Pioneering portfolio companies and other biotech partners.

Models and products

• Autonomous AI scientists. End-to-end laboratory-experiment-execution capability.
• Autonomous-laboratory infrastructure. Physical-laboratory infrastructure for autonomous experimental execution.
• Continued commercial-development. Through 2024 to 2026.

Distribution channels include direct commercial-development relationships.

Benchmarks and standing

Lila Sciences's evaluation framework focuses on autonomous-laboratory experimental-throughput and commercial-development metrics rather than horizontal foundation-model leaderboards. The autonomous-laboratory infrastructure has been characterized in AI-for-science industry coverage as a distinctive autonomous-AI approach.

Leadership

As of April 2026, Lila Sciences's senior leadership includes:

• Geoffrey von Maltzahn, Co-Founder and Chief Executive Officer. Flagship Pioneering general partner.
• Senior research and engineering leadership across the autonomous-laboratory program.

Funding and backers

• Series A (March 2025): $200 million at approximately $1.3 billion valuation, led by ARCH Venture Partners with Flagship Pioneering, General Catalyst, and other investors.
• Earlier capital: Flagship Pioneering venture-creation funding.

Industry position

Lila Sciences occupies a distinctive position as one of the principal commercial autonomous-AI-for-science startups, with the autonomous-laboratory infrastructure, the Flagship Pioneering venture-creation backing, and ARCH Venture Partners Series A backing.

Competitive landscape

• FutureHouse. Direct nonprofit AI-for-science peer with different open-research positioning.
• Isomorphic Labs, EvolutionaryScale, Inceptive, Hippocratic AI. Biology-AI peers.
• Recursion Pharmaceuticals, Insitro, Schrödinger, Generate Biomedicines. Biology-AI peers with different drug-discovery focus.
• Flagship Pioneering. Founder organization. Flagship-portfolio cooperation.

Outlook

• The continued autonomous-laboratory infrastructure scale-out through 2026 to 2027.
• Continued commercial-development with Flagship Pioneering portfolio companies.
• The Series B or adjacent fundraising timeline.

Sources

• Lila Sciences official site. Company reference.
• Lila Sciences Series A announcement. March 2025 funding announcement.
• Flagship Pioneering. Founder organization.
• ARCH Venture Partners. Lead Series A investor.
• Geoffrey von Maltzahn LinkedIn. Co-Founder reference.